- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ...

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting SYDNEY, AUSTRALIA, Sept. 08, 2025 ...

Biomed Industries, Inc. to Present Phase 2 Results on NA-931-a First-in Class Alternative to Injectables for the Treatment of Obesity-EASD 2025- Vienna-Austria We believe the future of obesity ...

SYDNEY, AUSTRALIA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases ...

As the Supreme Court of Georgia tests out two minutes of uninterrupted oral argument inspired by the U.S. Supreme Court's altered approach, appellate litigators are sharing their thoughts. Arguing on ...

Have you ever opened a spreadsheet and felt overwhelmed by a sea of unformatted numbers, struggling to make sense of the data? Whether it’s a financial report, survey results, or a project timeline, ...

Department of Education and Educational Innovation, Faculty of Law, Education and Humanities, European University of Madrid, Villaviciosa de Odón, Spain Background: Educational institutions promote ...

The new decentralized format for the 2025 NHL Draft didn't quite go as planned on Friday night. And that's putting it mildly. This year, they opted for several new angles, including NHL executives and ...

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a ...

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced the acceptance of multiple abstracts for presentation at three significant upcoming congresses focusing on angioedema, ...